Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting
01 10월 2021 - 9:43PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that the company will present preclinical data from its
multiplex edited allogeneic CAR T research targeting CD5-positive
hematologic malignancies. The data will be presented in a poster
titled “CD5 knockout enhances the potency of multiplex base-edited
allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell
malignancies” at the Society for Immunotherapy of Cancer’s (SITC)
36th Annual Meeting. The conference is being held Nov. 10-14, 2021.
“The ability to create a large number of simultaneous multiplex
edits in T-cells could provide CAR T and other cell therapies with
features that may dramatically enhance their therapeutic potential
in treating a range of cancer indications,” said Giuseppe
Ciaramella, Ph.D., president and chief scientific officer of Beam.
“This approach takes unique advantage of base editing to create a
highly-edited cell therapy as another potential treatment option
for patients with T-cell malignancies and provides a model system
to test the potential for loss of CD5 expression to be a general
mechanism for gene edited CAR T cell therapies that result in more
durable responses. We look forward to presenting details on this
work at SITC and continuing our evaluation of these and other edits
to enhance our future CAR T programs.”
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company
committed to establishing the leading, fully integrated platform
for precision genetic medicines. To achieve this vision, Beam has
assembled a platform that includes a suite of gene editing and
delivery technologies and is in the process of building internal
manufacturing capabilities. Beam’s suite of gene editing
technologies is anchored by base editing, a proprietary technology
that enables precise, predictable and efficient single base
changes, at targeted genomic sequences, without making
double-stranded breaks in the DNA. This enables a wide range of
potential therapeutic editing strategies that Beam is using to
advance a diversified portfolio of base editing programs. Beam is a
values-driven organization committed to its people, cutting-edge
science, and a vision of providing life-long cures to patients
suffering from serious diseases.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Investors are
cautioned not to place undue reliance on these forward-looking
statements, including, but not limited to, statements related to:
our planned base editing data presentations at upcoming scientific
conferences; our ability to enhance the therapeutic potential of
CAR T and other cell therapies in treating a range of cancer
indications; and the therapeutic applications and potential of our
technology, including our ability to develop life-long, curative,
precision genetic medicines for patients through base editing. Each
forward-looking statement is subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statement, including, without
limitation, risks and uncertainties related to: our ability to
develop, obtain regulatory approval for, and commercialize our
product candidates, which may take longer or cost more than
planned; our ability to raise additional funding, which may not be
available; our ability to obtain, maintain and enforce patent and
other intellectual property protection for our product candidates;
the potential impact of the COVID-19 pandemic; that preclinical
testing of our product candidates and preliminary or interim data
from preclinical and clinical trials may not be predictive of the
results or success of ongoing or later clinical trials; that
enrollment of our clinical trials may take longer than expected;
that our product candidates may experience manufacturing or supply
interruptions or failures; risks related to competitive products;
and the other risks and uncertainties identified under the headings
“Risk Factors Summary” and “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2020, our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2021, our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021,
and in any subsequent filings with the Securities and Exchange
Commission. These forward-looking statements (except as otherwise
noted) speak only as of the date of this press release. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by applicable
law.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024